TY - JOUR
T1 - MACOP-B treatment for advanced stage diffuse large cell lymphoma
T2 - A multicenter Italian study
AU - Vitolo, Umberto
AU - Bertini, Marilena
AU - Tarella, Corrado
AU - Bertoncelli, Maria C.
AU - Gallamini, Andrea
AU - Gallo, Eugenio
AU - Gatti, Anna M.
AU - Ghio, Riccardo
AU - Levis, Alessandro
AU - Luxi, Giovanni
AU - Marchi, Luciano
AU - Novarino, Anna
AU - Orlandi, Ester
AU - Orsucci, Lorella
AU - Ricciuti, Franco
AU - Rota-Scalabrini, Delia
AU - Scassa, Enzo
AU - Bernasconi, Carlo
AU - Pileri, Alessandro
AU - Resegotti, Luigi
PY - 1989
Y1 - 1989
N2 - Seventy-one patients with advanced stage diffuse large cell lymphoma were treated with MACOP-B. Sixty-nine per cent of patients achieved a complete response (CR), 10% a partial remission, while 11% had no response and 10% died because of toxicity. The CR rate was adversely affected by immunoblastic type, poor performance status and bone marrow involvement. Two-year survival for all 71 patients was 55% and 2-year disease-free survival (DFS) for the 49 CRs was 73%. Relapses were lower (P <0.05) in patients achieving CR in 8 weeks or less (DFS 83% vs. 59%) and in patients without tumor bulk (DFS 87% vs. 54%). Overall toxicity was acceptable with mucositis proving to be the most frequent severe side-effect. However, treatment-related deaths were unacceptably high in patients over 59 years of age (30% vs. 7%). Thus for the elderly MACOP-B is potentially lethal and must be used cautiously. These preliminary results confirm the effectiveness of MACOP-B. The delay of response and/or the presence of tumor bulk may be important prognostic factors in identifying a subset of poor risk patients with a high incidence of relapse.
AB - Seventy-one patients with advanced stage diffuse large cell lymphoma were treated with MACOP-B. Sixty-nine per cent of patients achieved a complete response (CR), 10% a partial remission, while 11% had no response and 10% died because of toxicity. The CR rate was adversely affected by immunoblastic type, poor performance status and bone marrow involvement. Two-year survival for all 71 patients was 55% and 2-year disease-free survival (DFS) for the 49 CRs was 73%. Relapses were lower (P <0.05) in patients achieving CR in 8 weeks or less (DFS 83% vs. 59%) and in patients without tumor bulk (DFS 87% vs. 54%). Overall toxicity was acceptable with mucositis proving to be the most frequent severe side-effect. However, treatment-related deaths were unacceptably high in patients over 59 years of age (30% vs. 7%). Thus for the elderly MACOP-B is potentially lethal and must be used cautiously. These preliminary results confirm the effectiveness of MACOP-B. The delay of response and/or the presence of tumor bulk may be important prognostic factors in identifying a subset of poor risk patients with a high incidence of relapse.
UR - http://www.scopus.com/inward/record.url?scp=0024462366&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024462366&partnerID=8YFLogxK
U2 - 10.1016/0277-5379(89)90102-8
DO - 10.1016/0277-5379(89)90102-8
M3 - Article
C2 - 2480242
AN - SCOPUS:0024462366
VL - 25
SP - 1441
EP - 1449
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 10
ER -